Wire Stories
OliX Pharmaceuticals Doses First Patient in Clinical Trial for RNAi Therapeutic OLX10212 for Dry and Wet Age-related Macular Degeneration
SUWON, South Korea–(BUSINESS WIRE)–#AMD—OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the first patient has been...